Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN80812769
ISRCTN80812769
Completed
Phase 3

A randomised phase III clinical trial investigating the effect of FRAGMin® Added to standard Therapy In patients with lung Cancer

Velindre NHS Trust (UK)0 sites2,202 target enrollmentJuly 8, 2005
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Velindre NHS Trust (UK)
Enrollment
2202
Status
Completed
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

2009 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/19807917 protocol 2016 Results article in http://www.ncbi.nlm.nih.gov/pubmed/26700124 results 2016 Results article in https://www.ncbi.nlm.nih.gov/pubmed/27439472 results

Registry
who.int
Start Date
July 8, 2005
End Date
October 31, 2011
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Velindre NHS Trust (UK)

Eligibility Criteria

Inclusion Criteria

  • •Patients with histopathologically or cytologically confirmed primary lung cancer of any stage or histology.

Exclusion Criteria

  • •1\. Patients with other intrathoracic tumours (e.g. carcinoid, mesothelioma, lymphoma, lung metastases from another primary site)
  • •2\. Any previous illness or treatment likely to interfere with protocol treatment or comparisons
  • •3\. Known cerebral metastases
  • •4\. Haemoptysis of CTC Grade two (symptomatic haemoptysis requiring medical intervention) or above
  • •5\. Known bleeding diathesis
  • •6\. Known pregnancy or lactation
  • •7\. Known allergy to heparin
  • •8\. Platelet count lower than 100 x 10^9/l
  • •9\. Renal impairment with serum creatinine greater than 150 µmol/l
  • •10\. Patients who have received therapeutic anticoagulation in the last 12 months

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
IgNiTE: Immunoglobulin in the treatment of encephalitisEncephalitisNervous System DiseasesEncephalitis, myelitis and encephalomyelitis, unspecified
ISRCTN15791925niversity of Oxford18
Completed
Phase 3
A prospective randomised phase III study of observation versus screening MRI and preemptive treatment in castrate resistant prostate cancer patients with spinal metastasis
ISRCTN74112318Institute of Cancer Research Experimental Cancer Medicine Centre541
Completed
Not Applicable
Brief intervention for weight lossObesity in primary careNutritional, Metabolic, EndocrineObesity
ISRCTN26563137niversity of Oxford (UK)1,882
Completed
Phase 3
A phase III study to investigate a vaccine against COVID-19COVID-19 (SARS-CoV-2 infection)Infections and Infestations
ISRCTN89951424niversity of Oxford10,300
Completed
Not Applicable
Evaluation of a computer aid for assessing stomach symptoms
ISRCTN12595588niversity of Durham (UK)530